Revance Therapeutics: The Real Threat To AbbVie's Dividend

|
About: Revance Therapeutics, Inc. (RVNC), Includes: ABBV
by: Robert Falcone
This article is exclusive for subscribers.
Robert Falcone
Long-term horizon, value, Deep Value
Summary

DaxiBotulinumToxinA (Daxi) is Revance Therapeutic's Phase III competitor to Allergan's BOTOX.

Following successful completion of the SAKURA trial Revance is expecting initial launch of DAXI in 2020 for Glabellar lines.

Expected cosmetic and therapeutic approvals in the next few years should result in significant share price appreciation, mostly coming at AbbVie's expense.

Editor's note: Seeking Alpha is proud to welcome Robert Falcone as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free